1.
Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
by GEERTS, William H
Chest, 2004, Vol.126 (3), p.338S-400S
2.
Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II)
by Serruys, Patrick W
The Lancet (British edition), 1998, Vol.352 (9129), p.673-681
3.
Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials
by Ruff, Christian T, Dr
The Lancet (British edition), 2014, Vol.383 (9921), p.955-962
4.
Stroke prevention in atrial fibrillation
by Freedman, Ben, Prof
The Lancet (British edition), 2016, Vol.388 (10046), p.806-817
5.
Edoxaban versus enoxaparin–warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial
by Goette, Andreas, Prof
The Lancet (British edition), 2016, Vol.388 (10055), p.1995-2003
6.
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation
by Miller, Corey S., BA
The American journal of cardiology, 2012, Vol.110 (3), p.453-460
7.
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
by Hijazi, Ziad, Dr
The Lancet (British edition), 2016, Vol.387 (10035), p.2302-2311
8.
Deep vein thrombosis and pulmonary embolism
by Di Nisio, Marcello, Dr
The Lancet (British edition), 2016, Vol.388 (10063), p.3060-3073
9.
Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of...
by Wallentin, Lars, Prof
The Lancet (British edition), 2010, Vol.376 (9745), p.975-983
10.
Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial
by Mega, Jessica L, Dr
The Lancet (British edition), 2015, Vol.385 (9984), p.2280-2287
11.
International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer
by Farge, Dominique, Prof
The lancet oncology, 2016, Vol.17 (10), p.e452-e466
12.
Acute myocardial infarction
by Reed, Grant W, MD
The Lancet (British edition), 2016, Vol.389 (10065), p.197-210
13.
Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism
by Eriksson, Bengt I
Annual review of medicine, 2011, Vol.62 (1), p.41-57
14.
An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease
by James, Stefan K
The American heart journal, 2005, Vol.149 (4), p.619-626
15.
Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial
by Turpie, Alexander GG, MD
The Lancet (British edition), 2009, Vol.373 (9676), p.1673-1680
16.
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial
by Lassen, Michael Rud, Dr
The Lancet (British edition), 2010, Vol.375 (9717), p.807-815
17.
A guide to immunotherapy for COVID-19
by van de Veerdonk, Frank L
Nature medicine, 2022-01-01, Vol.28 (1), p.39-50
18.
Trends in Prescribing Oral Anticoagulants in Canada, 2008–2014
by Weitz, Jeffrey I., MD
Clinical therapeutics, 2015, Vol.37 (11), p.2506-2514.e4
19.
Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials
by Cavender, Matthew A, MD
The Lancet (British edition), 2014, Vol.384 (9943), p.599-606
20.
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
by Chakravarty, Tarun, MD
The Lancet (British edition), 2017, Vol.389 (10087), p.2383-2392
